Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2020 | Story Loenie Bolleurs | Photo Charl Devenish
Saajida Abdulla believes great leaders are ambitious, driven, and aspire for transformation, but never purely for themselves. They are ambitious for others and possess an indefinite will to do whatever is necessary in service of this greater cause.

Coming from a strong business and entrepreneurial background, Saajida Abdulla is currently serving her Industrial Psychology internship in the Department of Organisational Development and Employee Wellness at the University of the Free State (UFS). 

Abdulla’s academic background includes several degrees in both psychology and business. After completing an honours degree in Business Sciences, she worked in the retail sector for several years. 

However, she still felt unfulfilled in her career path and returned to the world of academia to combine her passion for psychology and her inherent business strengths by pursuing further studies in Industrial Psychology. 

An interview with Abdulla sheds light on some of her dreams, inspirations, and challenges. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

I am inspired by STRONG WOMEN LEADERS, those who are accelerants for change, who have pushed through obstacles, challenged the status quo, and strived for transformation in their space – woman branded with tenacity, grit, resilience, and the vision to lead others to excellence.

My greatest inspiration is my mother. Her strength of character, resilience, and perseverance in overcoming adversity is what inspires me to keep going and be the best I can be. 

I am inspired by STRONG WOMEN LEADERS, those who are accelerants for change, who have pushed through obstacles, challenged the status quo, and strived for transformation in their space. - Saajida Abdulla

What are some challenges you have faced in your life that have made you a better woman?

If I had to single out some of the challenges I have faced, I would say failure. The taste of failure and disappointment has propelled me to keep pushing myself and to not allow situations to define me. I have learnt to view failure as nothing but a temporary setback, because if you allow the feelings of failure and disappointment to halt your growth, you will never evolve. 

What advice would you give to the 15-year-old you?

Your life has been designed by the best of architects, and even though you may not understand all the turns and detours, they are all absolutely necessary to take you to the exact places you need to be. On this journey, you will also encounter setbacks and failure, but embrace it, for it will lead to the evolution of your success. 

What would you say makes you a champion woman [of the UFS]?

I am honoured to be considered as one of the UFS’s champion women, and I believe it is inherently linked to my strive for great leadership. I critically evaluate and challenge situations, provide a vision for innovative problem solving, and direct change and transformation within all areas of my personal and professional life. However, the greatest quality that makes me a champion woman of the UFS, is my fundamental purpose to make a difference in the lives of others.

 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept